Cellular pharmacology of 2′,3′-didehydro-2′,3′-dideoxythymidine (D4T) in human peripheral blood mononuclear cells
1990; Elsevier BV; Volume: 39; Issue: 9 Linguagem: Inglês
10.1016/0006-2952(90)90418-k
ISSN1873-2968
AutoresZhu Zhou, Hsu‐Tso Ho, Michael J. M. Hitchcock, Jean‐Pierre Sommadossi,
Tópico(s)Viral-associated cancers and disorders
ResumoStavudine (d4T) is used extensively as part of HAART in resource poor settings, despite its toxicities. The revised WHO guidelines specify replacement of d4T with less toxic but more expensive drugs when feasible, and that d4T doses be standardized to 30 mg twice daily (bid) (irrespective of body-weight), from the approved 40 mg bid in adults (body-weight ⩾60 kg). Therefore, an in silico population pharmacokinetic and biochemical model was utilized to compare relative efficacies of the two doses in humans. Assessment of predicted quartile ranges of simulated concentrations of the triphosphate of d4T suggested sufficient trough concentrations to inhibit wild type HIV-1 reverse transcriptase at the reduced dose, lending support to the revised WHO recommendations.
Referência(s)